» Authors » Marcin Osiecki

Marcin Osiecki

Explore the profile of Marcin Osiecki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 74
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Derda E, Meglicka M, Wiernicka A, Osiecki M, Kierkus J, Szymanska E
Acta Paediatr . 2025 Jan; PMID: 39757999
Aim: We evaluated the frequency and severity of COVID-19, and vaccination status, in children with different forms of inflammatory bowel disease (IBD). Methods: This was a prospective, observational cohort study...
2.
Brylak J, Nowak J, Dybska E, Glapa-Nowak A, Kierkus J, Osiecki M, et al.
Medicina (Kaunas) . 2024 Aug; 60(8). PMID: 39202524
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), often necessitates long-term treatment and hospitalizations and also may require surgery. The ( rs3197999 polymorphism is strongly...
3.
Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Matuszczyk M, Kierkus J
J Pediatr Gastroenterol Nutr . 2024 Mar; 79(1):54-61. PMID: 38477410
Objectives: The severe course of inflammatory bowel diseases (IBDs) refractory to advanced therapies in children results in the search for new therapeutic methods. The aim of this study was to...
4.
Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Kierkus J
Children (Basel) . 2023 Jan; 10(1). PMID: 36670562
Background: Inflammatory bowel diseases in children are characterized by a wide variety of symptoms and often a severe clinical course. In the treatment, we aimed to induce and maintain remission....
5.
Glapa-Nowak A, Szczepanik M, Banaszkiewicz A, Kwiecien J, Szaflarska-Poplawska A, Grzybowska-Chlebowczyk U, et al.
Med Sci Monit . 2022 Sep; 28:e937842. PMID: 36101481
BACKGROUND This study aimed to evaluate the C-reactive protein-to-albumin (CRP/albumin) ratio at diagnosis of pediatric inflammatory bowel disease (IBD). MATERIAL AND METHODS Serum CRP/albumin ratio was calculated for patients with...
6.
Matuszczyk M, Meglicka M, Wiernicka A, Jarzebicka D, Osiecki M, Kotkowicz-Szczur M, et al.
J Clin Med . 2022 Jul; 11(14). PMID: 35887910
(1) Background: The CDED + PEN (partial enteral nutrition) is a promising method of nutritional treatment in active Crohn’s disease (CD). An increase in fecal calprotectin (FCP) level—a marker of...
7.
Nowak J, Glapa-Nowak A, Banaszkiewicz A, Iwanczak B, Kwiecien J, Szaflarska-Poplawska A, et al.
Genes (Basel) . 2021 Dec; 12(12). PMID: 34946883
The human leukocyte antigen (HLA) allele group HLA-DQA1*05 predisposes to ulcerative colitis (UC) and is associated with the development of antibodies against infliximab in patients with inflammatory bowel disease (IBD)....
8.
Glapa-Nowak A, Szczepanik M, Banaszkiewicz A, Iwanczak B, Kwiecien J, Szaflarska-Poplawska A, et al.
Children (Basel) . 2021 Nov; 8(11). PMID: 34828659
Deleted in malignant brain tumours 1 protein (DMBT1) and surfactant protein D (SFTPD) are antimicrobial peptides previously linked to inflammatory bowel disease (IBD) susceptibility. This study attempts to link the...
9.
Szymanska E, Dadalski M, Sieczkowska-Golub J, Jarzebicka D, Meglicka M, Osiecki M, et al.
J Clin Med . 2021 Jul; 10(14). PMID: 34300342
Background: Infusion reactions (IRs) are the most common adverse events (AEs) of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). Prophylactic premedication (PM) with corticosteroids or antihistamines prior...
10.
Fabiszewska S, Derda E, Szymanska E, Osiecki M, Kierkus J
J Clin Med . 2021 Jul; 10(13). PMID: 34279480
Vedolizumab (vedo) is effective for induction and maintenance of remission in adults with inflammatory bowel disease (IBD). Pediatric data are still limited, especially for the youngest children with very early...